Compare Gap Inc (GAP) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Eli Lilly And Co — how do they compare? Gap Inc trades at $23.36 (market cap $8.21B), while Eli Lilly And Co trades at $1,169.74 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 126.7× Gap Inc's market cap, and Gap Inc pays the higher dividend (3%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Eli Lilly And Co for 93 Days on average.
| GAP | LLY | |
|---|---|---|
Market Cap | $8.21B | $1.04T |
Volume | 5,192,917 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $1.28K |
52-Week Low | $18.35 | $799.57 |
Typical Hold Time | 37 Days | 93 Days |
Enterprise Value | $11.44B | $1.09T |
Dividend Yield | 3% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap (GAP) trades at $23.61, down 0.76% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.11 and robust profitability, including a 33.78% ROE. Recent earnings beat estimates in Q1 and Q2 2026, and the company is expanding into music partnerships to engage customers. Cash flow from operations remains healthy at $1.49 billion for 2025.
The outlook is positive given Gap's attractive valuation, earnings momentum, and strategic initiatives. Key risks include competitive pressures in retail and reliance on brand revitalization. Analyst consensus is a $25.67 price target, suggesting upside potential, but investors should monitor execution of growth strategies amid economic uncertainties.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
